Omeros Q3 OMIDRIA rev $30M (+4.1% QoQ); net loss narrows; FDA CRL for narsoplimab

OMEROS CORP

2021-Q3 EPS reported -$1.39 revenue$79,889,000

OMIDRIA revenue $30.0M in Q3, up 4.1% from Q2 $28.8M; driven by ASC growth.
Net loss $22.7M ($0.36/sh) improved from $28.6M ($0.46/sh) in Q2; cash $50.4M.
CMS confirmed separate payment for OMIDRIA in ASC for 2022; NOPAIN Act has 34 Senate/74 House sponsors.
Received FDA Complete Response Letter for narsoplimab BLA in HSCT-TMA; preparing Type A meeting.
Phase 1 data for OMS906 shows high alternative pathway suppression; moving directly into PNH patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.